Tumour immune rejection triggered by activation of α2-adrenergic receptors
<p>Immunotherapy based on immunecheckpoint blockade (ICB) using antibodies induces rejection of tumours and brings clinical benefit in patients with various cancer types. However, tumours often resist immune rejection. Ongoing efforts trying to increase tumour response rates are based on combi...
| Main Authors: | , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Springer Nature
2023
|